Contents
Issue 143 • June 2024
In association with
In Depth
Lula’s progress plan for Brazil: A year on
How sham patents are hurting the pharma industry
Tracking the opioid lawsuit settlements amidst calls for oversight
Cell and gene therapy landscape in the US
Q&A: Cell and gene therapy value assessments need a rework to allow access
Q&A: Pharmaceutical discovery through a gravitational lens
Thematic Take
ESG in the pharma sector
Powered by
